Taro Pharmaceutical Industries (NYSE:TARO) Stock Price Passes Above 200 Day Moving Average of $0.00

Taro Pharmaceutical Industries Ltd. (NYSE:TARO)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $74.15. Taro Pharmaceutical Industries shares last traded at $73.54, with a volume of 15,568 shares traded.

Several equities research analysts have recently issued reports on TARO shares. Zacks Investment Research raised shares of Taro Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 7th. TheStreet lowered shares of Taro Pharmaceutical Industries from a “c” rating to a “d+” rating in a research report on Wednesday, May 19th. Finally, HC Wainwright lowered their price target on shares of Taro Pharmaceutical Industries from $81.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, June 2nd.

The business’s fifty day simple moving average is $73.37. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -7.39 and a beta of 0.93.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings results on Tuesday, May 18th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.92 by ($1.70). The firm had revenue of $148.35 million for the quarter, compared to analyst estimates of $147.33 million. Taro Pharmaceutical Industries had a negative net margin of 70.43% and a positive return on equity of 8.07%. Equities research analysts forecast that Taro Pharmaceutical Industries Ltd. will post 3.87 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARO. Inspire Advisors LLC acquired a new stake in Taro Pharmaceutical Industries during the 4th quarter valued at $81,000. Phoenix Holdings Ltd. bought a new position in Taro Pharmaceutical Industries during the 4th quarter valued at $200,000. Tudor Investment Corp Et Al bought a new position in Taro Pharmaceutical Industries during the 1st quarter valued at $213,000. PDT Partners LLC bought a new position in Taro Pharmaceutical Industries during the 1st quarter valued at $242,000. Finally, Van ECK Associates Corp bought a new position in Taro Pharmaceutical Industries during the 1st quarter valued at $246,000. 12.45% of the stock is owned by institutional investors and hedge funds.

Taro Pharmaceutical Industries Company Profile (NYSE:TARO)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

See Also: No Load Funds

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.